Zandelisib
A phosphoinositide 3-kinase inhibitor used in cancer treatment
Zandelisib is an investigational drug that functions as a selective inhibitor of the phosphoinositide 3-kinase (PI3K) pathway, specifically targeting the delta isoform of PI3K. It is being developed for the treatment of various types of cancer, particularly B-cell malignancies.
Mechanism of Action[edit | edit source]
Zandelisib works by inhibiting the PI3K delta isoform, which is a critical component of the PI3K/AKT/mTOR signaling pathway. This pathway is involved in cell growth, proliferation, and survival, and is often dysregulated in cancer cells. By selectively targeting the delta isoform, zandelisib aims to reduce the proliferation of malignant B-cells while minimizing effects on normal cells.
Clinical Development[edit | edit source]
Zandelisib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with various B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Early-phase trials have shown promising results, with significant anti-tumor activity observed in patients who have relapsed or are refractory to other treatments.
Administration and Dosage[edit | edit source]
Zandelisib is administered orally, which provides a convenient route of administration compared to intravenous therapies. The dosing regimen is designed to optimize efficacy while minimizing adverse effects, with ongoing studies to determine the optimal dosing schedule.
Adverse Effects[edit | edit source]
As with other PI3K inhibitors, zandelisib can cause a range of side effects. Common adverse effects include diarrhea, fatigue, and neutropenia. More serious side effects, such as infections and liver toxicity, have also been observed, necessitating careful monitoring during treatment.
Research and Development[edit | edit source]
The development of zandelisib is part of a broader effort to create targeted therapies that can more effectively treat cancer with fewer side effects than traditional chemotherapy. Research is ongoing to explore its use in combination with other therapies, such as monoclonal antibodies and immune checkpoint inhibitors, to enhance its therapeutic potential.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
